Jan Johansson
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$15.4MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $15.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase II Subcutaneous CS6253 9-Month Chronic Toxicology GLP Study in Cynomolgus Monkeys to assess Safety, Tolerability and PK | $2.3M | ARTERY THERAPEUTICS INC |
| Sep 9, 2025 | NIH | SBIR Phase II Manufacturing of ABCA1 agonist small molecule peptide CS6253 to support chronic toxicology studies in Wistar rats and Cynomolgus monkeys | $2.5M | ARTERY THERAPEUTICS INC |
| Jan 15, 2023 | NIH | SBIR Phase II A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253 | $2.5M | ARTERY THERAPEUTICS INC |
| Jan 11, 2023 | NIH | SBIR Phase II A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253 | $2.5M | ARTERY THERAPEUTICS INC |
| Sep 21, 2021 | NIH | SBIR Phase II A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253 | $499K | ARTERY THERAPEUTICS INC |
| May 15, 2020 | NIH | SBIR Phase II CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease | $2.4M | ARTERY THERAPEUTICS INC |
| May 11, 2020 | NIH | SBIR Phase II CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease | $2.4M | ARTERY THERAPEUTICS INC |
| May 28, 2019 | NIH | SBIR Phase II CS6253 development for the treatment of apoE4 driven dementia includingAlzheimer's disease | $480K | ARTERY THERAPEUTICS INC |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#15
Awards as PI#190
Patents#273
Companies
- ARTERY THERAPEUTICS INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.